Lantheus’ third quarter was marked by a negative market reaction, as investors responded to lower operating margins and significant leadership changes despite revenue exceeding Wall Street’s expectations. Management pointed to pricing stabilization in the prostate cancer imaging franchise and continued growth in its DEFINITY ultrasound agent as key drivers. CEO Brian Markison highlighted, “Pricing stabilization across our accounts that began early in the third quarter has continued,” attributing the performance to disciplined commercial execution and ongoing customer education. However, higher operating expenses—including integration costs from recent acquisitions—pressured profitability.

Is now the time to buy LNTH? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Lantheus’s Q3 Earnings Call

• Roanna Clarissa Ruiz (Leerink Partners) asked about strategies driving higher-end guidance for PYLARIFY and Neuraceq. CEO Brian Markison cited stabilization in the PSMA market and expanded Neuraceq availability as key factors.
• Richard Newitter (Truist) inquired about potential major resets and visibility into 2026. Markison declined to provide specifics but noted account base stabilization and continued volume growth for PYLARIFY.
• Matthew Taylor (Jefferies) asked about the timing and rationale for management changes. Markison described his retirement as a personal decision and emphasized a seamless transition with interim CEO Mary Anne Heino.
• Yuan Zhi (B. Riley) questioned the competitive impact of cyclotron-produced agents like Gozellix. Markison reported minimal market share loss and consistent growth among smaller accounts.
• Pete Lucas for Larry Solow (CJS Securities) sought details on competitive positioning in Alzheimer’s imaging, particularly for MK-6240. Markison highlighted clinical differentiation and the evolving importance of tau imaging in disease management.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be watching (1) the pace of adoption and reimbursement for the new F-18 PSMA PET formulation and Alzheimer’s imaging agents, (2) the stability of PYLARIFY pricing and volume in a competitive market, and (3) the successful integration of recent acquisitions and management transitions. Progress on regulatory milestones and margin stabilization will be additional key signposts for tracking execution.

Lantheus currently trades at $54.28, down from $57.23 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free for active Edge members).

High-Quality Stocks for All Market Conditions

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.